AKBA Q2 2021 Earnings — Akebia Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

AKBAAkebia Therapeutics, Inc.

$365M

Q2 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$53M-41.3% YoY

Gross Profit

$418,0000.8% margin

Operating Income

-$79M-149.9% margin

Net Income

-$83M-156.9% margin

EPS (Diluted)

$-0.51

QoQ Revenue Growth

+1.2%

Cash Flow

Operating Cash Flow

-$63M

Free Cash Flow

-$63M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$612M

Total Liabilities

$437M

Stockholders' Equity

$175M

Cash & Equivalents

$247M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$53M	$90M	-41.3%
Gross Profit	$418,000	-$84M	+100.5%
Operating Income	-$79M	-$174M	+54.4%
Net Income	-$83M	-$176M	+52.8%

Revenue Segments

Product

$33M62%

License Collaboration And Other Revenue

$20M38%